MicroRNAs Determining Carcinogenesis by Regulating Oncogenes and Tumor Suppressor Genes During Cell Cycle

Zacharias       Fasoulakis; George       Daskalakis; Michail       Diakosavvas; Ioannis       Papapanagiotou; Marianna       Theodora; Arzou       Bourazan; Dimitra       Alatzidou; Athanasios       Pagkalos; Emmanuel    N.    Kontomanolis
Abstract

Aim: To provide a review considering microRNAs regulating oncogenes and tumor suppressor genes during the different stages of cell cycle, controlling carcinogenesis.
Methods: The role of microRNAs involved as oncogenes’ and tumor suppressor genes’ regulators in cancer was searched in the relevant available literature in MEDLINE, including terms such as “microRNA”, “oncogenes”, “tumor suppressor genes”, “metastasis”, “cancer” and others.
Results: MicroRNAs determine the expression levels of multiple cell cycle regulators, such as cyclins, cyclin dependent kinases and other major cell cycle activators including retinoblastoma 1 (RB- 1) and p53, resulting in alteration and promotion/inhibition of the cell cycle.
Conclusion: MicroRNAs are proven to have a key role in cancer pathophysiology by altering the expression profile of different regulator proteins during cell division cycle and DNA replication. Thus, by acting as oncogenes and tumor suppressor genes, they can either promote or inhibit cancer development and formation, revealing their innovative role as biomarkers and therapeutic tools.
Keywords: Cancer, metastasis, microRNA, oncogene, tumor suppressor gene, segregation.
Graphical Abstract

[1] 
Society AC. Cancer facts and figures. American Cancer Society 2018.
[2] 
Belmont JW, Boudreau A, Leal SM, et al. A haplotype map of the human genome. Nature  2005; 437(7063): 1299-320.
[http://dx.doi.org/10.1038/nature04226] 
[3] 
Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer  2015; 15(6): 321-33.
[http://dx.doi.org/10.1038/nrc3932] [PMID:  25998712] 
[4] 
Cell Signaling. Cell cycle control: G1 / S checkpoint. Cell Signal Tech  2019.https://www.cellsignal.com/contents/science-cst-pathways-cell-cycle-regulation/g1-s-checkpoint/pathways-cc-g1s
[5] 
Yang N, Sheridan AM. Cell cycle Encyclopedia of toxicology.  3rd ed. Ref Module Biomed Sci 2014; pp. 753-8.
[http://dx.doi.org/10.1016/B978-0-12-386454-3.00273-6] 
[6] 
Lambert SA, Jolma A, Campitelli LF, et al. The human transcription factors. Cell  2018; 172(4): 650-65.
[http://dx.doi.org/10.1016/j.cell.2018.01.029] [PMID:  29425488] 
[7] 
Salazar-Roa M, Malumbres M. Fueling the cell division cycle. Trends Cell Biol  2017; 27(1): 69-81.
[http://dx.doi.org/10.1016/j.tcb.2016.08.009] [PMID:  27746095] 
[8] 
Lim S, Kaldis P. CDKs, cyclins and CKIs: roles beyond cell cycle regulation. Development  2013; 140(15): 3079-93.
[http://dx.doi.org/10.1242/dev.091744] [PMID:  23861057] 
[9] 
Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol  2008; 9(11): 910-6.
[http://dx.doi.org/10.1038/nrm2510] [PMID:  18813291] 
[10] 
Sánchez I, Dynlacht BD. New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol  2005; 16(3): 311-21.
[http://dx.doi.org/10.1016/j.semcdb.2005.02.007] [PMID:  15840440] 
[11] 
Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer  2007; 7(7): 495-507.
[http://dx.doi.org/10.1038/nrc2169] [PMID:  17568790] 
[12] 
Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J  1993; 12(1): 53-63.
[http://dx.doi.org/10.1002/j.1460-2075.1993.tb05631.x] [PMID:  8428594] 
[13] 
Zhang Z, Roe SM, Diogon M, Kong E, El Alaoui H, Barford D. Molecular structure of the N-terminal domain of the APC/C subunit CDC27 reveals a homo-dimeric tetratricopeptide repeat architecture. J Mol Biol  2010; 397(5): 1316-28.
[http://dx.doi.org/10.1016/j.jmb.2010.02.045] [PMID:  20206185] 
[14] 
Giacinti C, Giordano A. RB and cell cycle progression. Oncogene  2006; 25(38): 5220-7.
[http://dx.doi.org/10.1038/sj.onc.1209615] [PMID:  16936740] 
[15] 
Lujambio A, Akkari L, Simon J, et al. Non-cell-autonomous tumor suppression by p53. Cell  2013; 153(2): 449-60.
[http://dx.doi.org/10.1016/j.cell.2013.03.020] [PMID:  23562644] 
[16] 
Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet  2001; 10(7): 699-703.
[http://dx.doi.org/10.1093/hmg/10.7.699] [PMID:  11257102] 
[17] 
Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer  2001; 1(3): 222-31.
[http://dx.doi.org/10.1038/35106065] [PMID:  11902577] 
[18] 
Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer  2006; 6(4): 259-69.
[http://dx.doi.org/10.1038/nrc1840] [PMID:  16557279] 
[19] 
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem  2010; 79: 351-79.
[http://dx.doi.org/10.1146/annurev-biochem-060308-103103] [PMID:  20533884] 
[20] 
Kontomanolis EN, Kalagasidou S, Fasoulakis Z. MicroRNAs as potential serum biomarkers for early detection of ectopic pregnancy. Cureus  2018; 10(3) e2344
[http://dx.doi.org/10.7759/cureus.2344] [PMID:  29796356] 
[21] 
Kontomanolis EN, Fasoulakis Z, Papamanolis V, et al. The impact of microRNAs in breast cancer angiogenesis and progression. MicroRNA  2019; 8(2): 101-9.
[http://dx.doi.org/10.2174/2211536607666181017122921] 
[22] 
Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem  2010; 56(11): 1733-41.
[http://dx.doi.org/10.1373/clinchem.2010.147405] [PMID:  20847327] 
[23] 
Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet  2009; 10(10): 704-14.
[http://dx.doi.org/10.1038/nrg2634] [PMID:  19763153] 
[24] 
Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther  2010; 18(1): 181-7.
[http://dx.doi.org/10.1038/mt.2009.207] [PMID:  19738602] 
[25] 
Shi T, Jiang R, Yu J, et al. SGOG-OV/AICE investigators. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. Br J Cancer  2018; 119(1): 12-8.
[http://dx.doi.org/10.1038/s41416-018-0036-7] [PMID:  29899395] 
[26] 
Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol  2008; 90(1): 1-7.
[http://dx.doi.org/10.1007/s11060-008-9624-3] [PMID:  18607543] 
[27] 
Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res  2008; 68(7): 2094-105.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-5194] [PMID:  18381414] 
[28] 
Lal A, Kim HH, Abdelmohsen K, et al. p16(INK4a) translation suppressed by miR-24. PLoS One  2008; 3(3) e1864
[http://dx.doi.org/10.1371/journal.pone.0001864] [PMID:  18365017] 
[29] 
Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett  2008; 582(10): 1564-8.
[http://dx.doi.org/10.1016/j.febslet.2008.03.057] [PMID:  18406353] 
[30] 
Shi L, Zhang J, Pan T, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res  2010; 1312: 120-6.
[http://dx.doi.org/10.1016/j.brainres.2009.11.056] [PMID:  19948152] 
[31] 
Wu J, Qian J, Li C, et al. miR-129 regulates cell proliferation by downregulating CDK6 expression. Cell Cycle  2010; 9(9): 1809-18.
[http://dx.doi.org/10.4161/cc.9.9.11535] [PMID:  20404570] 
[32] 
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology  2009; 50(1): 113-21.
[http://dx.doi.org/10.1002/hep.22919] [PMID:  19441017] 
[33] 
Feng M, Yu Q. miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit. Cell Cycle  2010; 9(2): 213-4.
[http://dx.doi.org/10.4161/cc.9.2.10502] [PMID:  20046097] 
[34] 
Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC. degli Uberti EC. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol  2005; 204(1): 280-5.
[http://dx.doi.org/10.1002/jcp.20282] [PMID:  15648093] 
[35] 
Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med  2008; 14(11): 1271-7.
[http://dx.doi.org/10.1038/nm.1880] [PMID:  18931683] 
[36] 
Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer  2008; 123(2): 372-9.
[http://dx.doi.org/10.1002/ijc.23501] [PMID:  18449891] 
[37] 
Liu Q, Fu H, Sun F, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res  2008; 36(16): 5391-404.
[http://dx.doi.org/10.1093/nar/gkn522] [PMID:  18701644] 
[38] 
Yu Z, Wang C, Wang M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol  2008; 182(3): 509-17.
[http://dx.doi.org/10.1083/jcb.200801079] [PMID:  18695042] 
[39] 
Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell  2009; 137(6): 1005-17.
[http://dx.doi.org/10.1016/j.cell.2009.04.021] [PMID:  19524505] 
[40] 
Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res  2008; 18(5): 549-57.
[http://dx.doi.org/10.1038/cr.2008.45] [PMID:  18379589] 
[41] 
Wang F, Fu XD, Zhou Y, Zhang Y. Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep  2009; 42(11): 725-30.
[http://dx.doi.org/10.5483/BMBRep.2009.42.11.725] [PMID:  19944013] 
[42] 
Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res  2007; 67(4): 1424-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-4218] [PMID:  17308079] 
[43] 
O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature  2005; 435(7043): 839-43.
[http://dx.doi.org/10.1038/nature03677] [PMID:  15944709] 
[44] 
Pickering MT, Stadler BM, Kowalik TF. miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene  2009; 28(1): 140-5.
[http://dx.doi.org/10.1038/onc.2008.372] [PMID:  18836483] 
[45] 
Díaz R, Silva J, García JM, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer  2008; 47(9): 794-802.
[http://dx.doi.org/10.1002/gcc.20580] 
[46] 
Lin RJ, Lin YC, Yu AL. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog  2010; 49(8): 719-27.
[http://dx.doi.org/10.1002/mc.20647] [PMID:  20623644] 
[47] 
Lee KH, Chen YL, Yeh SD, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene  2009; 28(38): 3360-70.
[http://dx.doi.org/10.1038/onc.2009.192] [PMID:  19597470] 
[48] 
Guo X, Guo L, Ji J, et al. miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun  2010; 398(1): 1-6.
[http://dx.doi.org/10.1016/j.bbrc.2010.05.082] [PMID:  20510161] 
[49] 
Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther  2008; 7(2): 255-64.
[http://dx.doi.org/10.4161/cbt.7.2.5297] [PMID:  18059191] 
[50] 
Huang L, Luo J, Cai Q, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer  2011; 128(8): 1758-69.
[http://dx.doi.org/10.1002/ijc.25509] [PMID:  20549700] 
[51] 
Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA  2006; 103(7): 2257-61.
[http://dx.doi.org/10.1073/pnas.0510565103] [PMID:  16461460] 
[52] 
Benetti R, Gonzalo S, Jaco I, et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol  2008; 15(3): 268-79.
[http://dx.doi.org/10.1038/nsmb.1399] [PMID:  18311151] 
[53] 
Wang Q, Li YC, Wang J, et al. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci USA  2008; 105(8): 2889-94.
[http://dx.doi.org/10.1073/pnas.0800178105] [PMID:  18287052] 
[54] 
Cloonan N, Brown MK, Steptoe AL, et al. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol  2008; 9(8): R127.
[http://dx.doi.org/10.1186/gb-2008-9-8-r127] [PMID:  18700987] 
[55] 
Malhas A, Saunders NJ, Vaux DJ. The nuclear envelope can control gene expression and cell cycle progression via miRNA regulation. Cell Cycle  2010; 9(3): 531-9.
[http://dx.doi.org/10.4161/cc.9.3.10511] [PMID:  20081371] 
[56] 
Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol  2008; 28(7): 2167-74.
[http://dx.doi.org/10.1128/MCB.01977-07] [PMID:  18212054] 
[57] 
Kim YK, Yu J, Han TS, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res  2009; 37(5): 1672-81.
[http://dx.doi.org/10.1093/nar/gkp002] [PMID:  19153141] 
[58] 
Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer  2007; 14(3): 791-8.
[http://dx.doi.org/10.1677/ERC-07-0129] [PMID:  17914108] 
[59] 
Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle  2009; 8(5): 736-41.
[http://dx.doi.org/10.4161/cc.8.5.7870] [PMID:  19221487] 
[60] 
Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem  2008; 283(44): 29897-903.
[http://dx.doi.org/10.1074/jbc.M804612200] [PMID:  18708351] 
[61] 
Qi J, Yu JY, Shcherbata HR, et al. microRNAs regulate human embryonic stem cell division. Cell Cycle  2009; 8(22): 3729-41.
[http://dx.doi.org/10.4161/cc.8.22.10033] [PMID:  19823043] 
[62] 
Butz H, Likó I, Czirják S, et al. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab  2010; 95(10): E181-91.
[http://dx.doi.org/10.1210/jc.2010-0581] [PMID:  20668041] 
[63] 
Glover DM, Hagan IM, Tavares ÁAM. Polo-like kinases: a team that plays throughout mitosis. Genes Dev  1998; 12(24): 3777-87.
[http://dx.doi.org/10.1101/gad.12.24.3777] [PMID:  9869630] 
[64] 
Shi W, Alajez NM, Bastianutto C, et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer  2010; 126(9): 2036-48.
[http://dx.doi.org/10.1002/ijc.24880] [PMID:  19739117] 
[65] 
Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet  2012; 3: 120.
[http://dx.doi.org/10.3389/fgene.2012.00120] [PMID:  22783274] 
[66] 
Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One  2009; 4(8) e6816
[http://dx.doi.org/10.1371/journal.pone.0006816] [PMID:  19714243] 
[67] 
Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett  2009; 275(1): 44-53.
[http://dx.doi.org/10.1016/j.canlet.2008.09.035] [PMID:  19006648] 
[68] 
Tryndyak VP, Ross SA, Beland FA, Pogribny IP. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog  2009; 48(6): 479-87.
[http://dx.doi.org/10.1002/mc.20484] [PMID:  18942116] 
[69] 
Tian YW, Shen Q, Jiang QF, Wang YX, Li K, Xue HZ. Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma. Minerva Med  2017; 108(2): 108-13.
[http://dx.doi.org/10.23736/S0026-4806.16.04616-4] [PMID:   27879964] 
[70] 
Wang X-P, Zhou J, Han M, et al. MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway. Oncotarget  2017; 8(8): 13264-76.
[http://dx.doi.org/10.18632/oncotarget.14807] [PMID:  28129650] 
[71] 
Misso G, Di Martino MT, De Rosa G, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids  2014; 3 e194
[http://dx.doi.org/10.1038/mtna.2014.47] [PMID:  25247240] 
[72] 
Wei W, Tang H, Tang L. MicroRNA-34a inhibits metastasis in liver cancer cells. Oncol Lett  2018; 16(6): 6960-5.
[http://dx.doi.org/10.3892/ol.2018.9555] [PMID:  30546428] 
[73] 
Pok S, Wen V, Shackel N, et al. Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis. J Gastroenterol Hepatol  2013; 28(9): 1545-54.
[http://dx.doi.org/10.1111/jgh.12216] [PMID:  23574010] 
[74] 
Han R, Chen X, Li Y, Zhang S, Li R, Lu L. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Manag Res  2019; 11: 2963-76.
[http://dx.doi.org/10.2147/CMAR.S202664] [PMID:  31114344] 
[75] 
Brock M, Samillan VJ, Trenkmann M, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J  2014; 35(45): 3203-11.
[http://dx.doi.org/10.1093/eurheartj/ehs060] [PMID:  22450430] 
[76] 
Wahlquist C, Jeong D, Rojas-Muñoz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature  2014; 508(7497): 531-5.
[http://dx.doi.org/10.1038/nature13073] [PMID:  24670661] 
[77] 
Xu LJ, Ouyang YB, Xiong X, Stary CM, Giffard RG. Post-stroke treatment with miR-181 antagomir reduces injury and improves long-term behavioral recovery in mice after focal cerebral ischemia. Exp Neurol  2015; 264: 1-7.
[http://dx.doi.org/10.1016/j.expneurol.2014.11.007] [PMID:  25433215] 
[78] 
Kwekkeboom RFJ, Sluijter JPG, van Middelaar BJ, et al. Increased local delivery of antagomir therapeutics to the rodent myocardium using ultrasound and microbubbles. J Control Release  2016; 222: 18-31.
[http://dx.doi.org/10.1016/j.jconrel.2015.11.020] [PMID:  26616760] 
[79] 
Briones C, Moreno M. Applications of Peptide Nucleic Acids (PNAs) and Locked Nucleic Acids (LNAs) in biosensor development. Anal Bioanal Chem  2012; 402(10): 3071-89.
[http://dx.doi.org/10.1007/s00216-012-5742-z] [PMID:  22297860] 
[80] 
Fabani MM, Abreu-Goodger C, Williams D, et al. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res  2010; 38(13): 4466-75.
[http://dx.doi.org/10.1093/nar/gkq160] [PMID:  20223773] 
[81] 
Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA  2010; 16(11): 2043-50.
[http://dx.doi.org/10.1261/rna.2414110] [PMID:  20855538] 
[82] 
Merhautová J, Vychytilová-Faltejsková P, Demlová R, et al. Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma. Physiol Res  2016; 65(Suppl. 4): S481-8.https://www.ncbi.nlm.nih.gov/pubmed/28006930
[PMID:  28006930] 
[83] 
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov  2017; 16(3): 203-22.
[http://dx.doi.org/10.1038/nrd.2016.246] [PMID:  28209991] 
[84] 
Yu F, Yao H, Zhu P, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell  2007; 131(6): 1109-23.
[http://dx.doi.org/10.1016/j.cell.2007.10.054] [PMID:  18083101] 
[85] 
Li Z, Shi K, Guan L, et al. ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett  2010; 584(11): 2291-7.
[http://dx.doi.org/10.1016/j.febslet.2010.03.040] [PMID:  20353787] 
[86] 
Zhao Y, Deng C, Wang J, et al. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat  2011; 127(1): 69-80.
[http://dx.doi.org/10.1007/s10549-010-0972-2] [PMID:  20535543] 
[87] 
Yong SL, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev  2007; 21: 1025-30.
[http://dx.doi.org/10.1101/gad.1540407] 
[88] 
Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther  2013; 21(1): 185-91.
[http://dx.doi.org/10.1038/mt.2012.180] [PMID:  23032975] 
[89] 
Cortez MA, Valdecanas D, Zhang X, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther  2014; 22(8): 1494-503.
[http://dx.doi.org/10.1038/mt.2014.79] [PMID:  24791940] 
[90] 
Coussens LM, Werb Z. Inflammation and cancer. Nature  2002; 420(6917): 860-7.
[http://dx.doi.org/10.1038/nature01322] [PMID:  12490959] 
[91] 
Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med  2009; 361(15): 1437-47.
[http://dx.doi.org/10.1056/NEJMoa0901282] [PMID:  19812400] 
[92] 
Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell  2013; 23(2): 186-99.
[http://dx.doi.org/10.1016/j.ccr.2012.12.020] [PMID:  23410973] 
[93] 
Nishimura M, Jung EJ, Shah MY, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov  2013; 3(11): 1302-15.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0159] [PMID:   24002999] 
[94] 
Rupaimoole R, Ivan C, Yang D, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene  2016; 35(33): 4312-20.
[http://dx.doi.org/10.1038/onc.2015.492] [PMID:  26725326] 
[95] 
Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA  2008; 105(13): 5166-71.
[http://dx.doi.org/10.1073/pnas.0800121105] [PMID:  18362358] 
[96] 
Stahlhut C, Slack FJ. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle  2015; 14(13): 2171-80.
[http://dx.doi.org/10.1080/15384101.2014.1003008] [PMID:  25714397] 
[97] 
Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res  2011; 71(10): 3563-72.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-3568] [PMID:  21471404] 
[98] 
Yoo B, Kavishwar A, Ross A, et al. Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Res  2015; 75(20): 4407-15.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-0888] [PMID:  26359455] 
[99] 
Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell  2009; 16(6): 498-509.
[http://dx.doi.org/10.1016/j.ccr.2009.10.014] [PMID:  19962668] 
[100] 
le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J  2007; 26(15): 3699-708.
[http://dx.doi.org/10.1038/sj.emboj.7601790] [PMID:  17627278] 
[101] 
Babar IA, Cheng CJ, Booth CJ, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA  2012; 109(26): E1695-704.
[http://dx.doi.org/10.1073/pnas.1201516109] [PMID:  22685206] 
[102] 
Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature  2015; 518(7537): 107-10.
[http://dx.doi.org/10.1038/nature13905] [PMID:  25409146] 
[103] 
Wang Y, Blelloch R. Cell cycle regulation by microRNAs in stem cells. Results Probl Cell Differ  2011; 53: 459-72.
[http://dx.doi.org/10.1007/978-3-642-19065-0_19] [PMID:  21630156] 
[104] 
Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific microRNAs. Dev Cell  2003; 5(2): 351-8.
[http://dx.doi.org/10.1016/S1534-5807(03)00227-2] [PMID:  12919684] 
[105] 
Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature  2010; 463(7281): 621-6.
[http://dx.doi.org/10.1038/nature08725] [PMID:  20054295] 
[106] 
Lichner Z, Páll E, Kerekes A, et al. The miR-290-295 cluster promotes pluripotency maintenance by regulating cell cycle phase distribution in mouse embryonic stem cells. Differentiation  2011; 81(1): 11-24.
[http://dx.doi.org/10.1016/j.diff.2010.08.002] [PMID:  20864249] 
[107] 
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell  2006; 126(4): 663-76.
[http://dx.doi.org/10.1016/j.cell.2006.07.024] [PMID:  16904174] 
[108] 
Zheng GXY, Ravi A, Calabrese JM, et al. A latent pro-survival function for the mir-290-295 cluster in mouse embryonic stem cells. PLoS Genet  2011; 7(5) e1002054
[http://dx.doi.org/10.1371/journal.pgen.1002054] [PMID:  21573140] 
[109] 
Hao J, Duan FF, Wang Y. MicroRNAs and RNA binding protein regulators of microRNAs in the control of pluripotency and reprogramming. Curr Opin Genet Dev  2017; 46: 95-103.
[http://dx.doi.org/10.1016/j.gde.2017.07.001] [PMID:  28753462] 
[110] 
Yuan K, Ai WB, Wan LY, Tan X, Wu JF. The miR-290-295 cluster as multi-faceted players in mouse embryonic stem cells. Cell Biosci  2017; 7: 38.
[http://dx.doi.org/10.1186/s13578-017-0166-2] [PMID:  28794853] 
[111] 
Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet  2008; 40(12): 1478-83.
[http://dx.doi.org/10.1038/ng.250] [PMID:  18978791] 
[112] 
Kanellopoulou C, Gilpatrick T, Kilaru G, et al. Reprogramming of polycomb-mediated gene silencing in embryonic stem cells by the miR-290 family and the methyltransferase Ash1l. Stem Cell Reports  2015; 5(6): 971-8.
[http://dx.doi.org/10.1016/j.stemcr.2015.10.001] [PMID:  26549848] 
[113] 
Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis  2011; 2 e204
[http://dx.doi.org/10.1038/cddis.2011.84] [PMID:  21881606] 
[114] 
Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell  2014; 26(2): 262-72.
[http://dx.doi.org/10.1016/j.ccr.2014.06.014] [PMID:  25117713] 
[115] 
Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. microRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA  2008; 105(50): 19678-83.
[http://dx.doi.org/10.1073/pnas.0811166106] [PMID:  19066217] 
[116] 
Kuo CH, Deng JH, Deng Q, Ying SY. A novel role of miR-302/367 in reprogramming. Biochem Biophys Res Commun  2012; 417(1): 11-6.
[http://dx.doi.org/10.1016/j.bbrc.2011.11.058] [PMID:  22138244] 
[117] 
Greer Card DA, Hebbar PB, Li L, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol  2008; 28(20): 6426-38.
[http://dx.doi.org/10.1128/MCB.00359-08] 
[118] 
Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell  2011; 8(4): 376-88.
[http://dx.doi.org/10.1016/j.stem.2011.03.001] [PMID:  21474102] 
[119] 
Lipchina I, Studer L, Betel D. The expanding role of miR-302-367 in pluripotency and reprogramming. Cell Cycle  2012; 11(8): 1517-23.
[http://dx.doi.org/10.4161/cc.19846] [PMID:  22436490] 
[120] 
Dolezalova D, Mraz M, Barta T, et al. MicroRNAs regulate p21(Waf1/Cip1) protein expression and the DNA damage response in human embryonic stem cells. Stem Cells  2012; 30(7): 1362-72.
[http://dx.doi.org/10.1002/stem.1108] [PMID:  22511267] 
[121] 
Liang Y, Li Y, Li Z, et al. Mechanism of folate deficiency-induced apoptosis in mouse embryonic stem cells: cell cycle arrest/apoptosis in G1/G0 mediated by microRNA-302a and tumor suppressor gene Lats2. Int J Biochem Cell Biol  2012; 44(11): 1750-60.
[http://dx.doi.org/10.1016/j.biocel.2012.07.014] [PMID:  22828209] 
Cite As